过继免疫治疗中DC-CIK的研究进展

目前,免疫细胞生物学和免疫分子生物学发展迅猛,由于其具备低毒性和高效率的特性,肿瘤免疫治疗在恶性肿瘤治疗中所起的作用引起了学者们的广泛关注,其中细胞介导的过继免疫治疗为当前研究的热点之一。过继免疫治疗(adoptive cellular immunotherapy,ACI)是目前恶性肿瘤治疗的新方向,它通过向细胞免疫功能低下者回输具有抗肿瘤活性的免疫细胞,直接杀伤或间接杀伤肿瘤细胞,使其获得抗肿瘤免疫力。树突状细胞(Dendritic cell DC)是专职抗原递呈细胞(antigen presenting cell APC)之一,在机体免疫应答的启始、调节、维持中发挥核心作用。细胞因子诱导的杀伤(cytokine induced killer CIK)细胞具有高效的MHC非限制性溶瘤活性,具有极其广泛的杀瘤范围。近年来,国内外大量研究表明,联合培养的DC-CIK抗肿瘤活性提升明显,患者预后生存期延长,效果显著。本文就DC与CIK生物学特点及抗肿瘤作用予以简要综述。

The Research of DC-CIK in Adoptive Cellular Immunotherapy

Currently, Immune cell biology and Immune molecular biology are developing rapidly. Due to characteristic of cancer immunotherapy with low toxicity and high efficiency, tumor immunotherapy in the treatment of malignant tumors have attracted wide attention of the scholars. Cell-mediated adoptive cellular immunotherapy treatment is one of the current research focuses. ACI, a new kind of treatment method for malignant tumor, can kill tumor cells by re-transfusing cancer patients the antitumor immune cells which has been cultured, subcultured and activated in vitro. Dendritic cell is a kind of powerful professional antigen-presenting cells and plays a central role in starting, regulating, and maintaining Immune responses. Cytokine-induced killer cells with efficient MHC non-restricted oncolytic activity have an extremely broad scope of killing tumor. In recent years, many studies suggest that anti-tumor activity of the joint training DC-CIK has improved significantly. Prognosis lifetime of patients can be extended significantly. This is a brief overview of DC and CIK biological feature and antitumor activity. The DC and CIK biology characteristics and anti-tumor effect will be reviewed in this brief.